Pharmaceuticals, Biotechnology and Life Sciences
GenSight Biologics, a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, has reported €22.1 million loss for 2016, which is increase of loss comparing last years €13.7 million.
Virbac has reported net profit of €34.6 million for 2016 which is 268% increase compared to 2015.
TiGenix has found in its acute hearth attack study that allogenic cardiac stem cells can be transplanted safely through the coronary tree.
Innate Pharma and Bristol-Myers Squibb have modified the clinical trial protocol for its ongoing Phase I/II trial evaluating the safety and tolerability of lirilumab in combination with Opdivo in patients with advanced refractory solid tumors.
Mylan has launched Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, a generic version of Pfizer’s Pristiq Tablets in U.S..
The popularity of cannabis in its raw form will increasingly be priced as a commodity
Pharmaceutical Daily has conducted an interview with Duke Rodriguez, the CEO of Ultra Health, the company that has opened the first pharmaceutical cannabis factory in the USA.
The Ultra Health CEO answered questions about hurdles of a cannabis company, as most banks in the US cannot legally do business with such companies, and what is the new administration in the White House stand on legalizing cannabis.
Synairgen has reported more positive data from its LOXL2 (lysyl oxidase-like 2 enzyme) inhibitor programme against the lung disease idiopathic pulmonary…
Oxford Pharmascience Group has posted full year loss before tax £1.9m, compared to 2015’s £3.9m, citing lower number of clinical…
Hikma Pharmaceuticals said on Friday that its US subsidiary West-Ward Pharmaceuticals Corp. has launched two doses of generic Pfizer’s Pristiq (Desvenlafaxine Succinate) ER Tablets.
Galapagos NV has started two new Phase 2 studies of filgotinib in small bowel Crohn`s disease and in fistulizing Crohn`s disease, both led by filgotinib collaboration partner Gilead Sciences.